Artivion, Inc. Common Stock (AORT)

Artivion (NYSE:AORT) reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for the U.S. launch of its NEXUS aortic repair system. Revenue rose to $123.8 million, with growth led

Margins slipped on ramp costs as the company eyes NEXUS and ARTIZEN milestones.

Medical device company Artivion (NYSE:AORT) beat Wall Street’s revenue expectations in Q3 2026, with sales up 9.2% year on year to $123.8 million. On the oth...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Medical device company Artivion (NYSE:AORT) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 9.2% year on year to $123.8...

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Medical device company Artivion (NYSE:AORT) will be announcing earnings results this Thursday after the bell. Here’s what to expect. Artivion beat analysts’ ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Artivion (NYSE:AORT) and its ...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

What a brutal six months it’s been for Artivion. The stock has dropped 29.1% and now trades at $25.57, rattling many shareholders. This may have investors wo...

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...

What Happened? Shares of medical device company Artivion (NYSE:AORT) jumped 2.5% in the afternoon session after Canaccord Genuity raised its price target on ...

Revenue grew 9% as heart valve and stent graft products drove results.

Artivion’s second quarter results were well received by the market, with performance driven by accelerating growth in its stent graft and On-X heart valve po...

Artivion (NYSE:AORT) reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined rou

Medical device company Artivion (NYSE:AORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.3% year on year to $125.8 ...

Medical device company Artivion (NYSE:AORT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.3% year on year to $125.8 mil...

Medical device company Artivion (NYSE:AORT) will be reporting earnings this Thursday after the bell. Here’s what to expect. Artivion met analysts’ revenue ex...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...